Showing results (291-300 of 354) with videos related to

Sort By:
Pageof 36
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 1, 1987
Cyclosporine toxicity: the effect of combined therapy using cyclosporine, azathioprine, and prednisoneM I Lorber, S M Flechner, C T Van Buren, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 17, 2012
Anti-TCRβ mAb induces long-term allograft survival by reducing antigen-reactive T cells and sparing regulatory T cellsY Miyahara, M Khattar, P M Schroder, et al.
Transplantation|February 1, 1988
The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipientsR M Lewis, P C Johnson, D Golden, et al.
Transplantation|May 1, 1993
Cyclosporine and rapamycin affect protein kinase C induction of the intracellular activation signal, activator of DNA replicationP M Kimball, R K Kerman, C T Van Buren, et al.
Transplantation|February 1, 1988
The impact of HLA A, B, and DR blood transfusions and immune responder status on cardiac allograft recipients treated with cyclosporineR H Kerman, C T van Buren, R M Lewis, et al.
Transplantation|May 1, 1993
15 AU81, a prostacyclin analog, potentiates immunosuppression and mitigates renal injury due to cyclosporineL J Dumble, S Gibbons, N Tejpal, et al.
Transplantation|March 27, 1994
The relationship among donor-recipient HLA mismatches, rejection, and death from coronary artery disease in cardiac transplant recipientsR H Kerman, P Kimball, S Scheinen, et al.
Transplantation|December 1, 1985
100 living-related kidney donor evaluations using digital subtraction angiographyS M Flechner, C M Sandler, G K Houston, et al.
Transplantation|January 1, 1990
Improved graft survival for flow cytometry and antihuman globulin crossmatch-negative retransplant recipientsR H Kerman, C T Van Buren, R M Lewis, et al.
Transplantation|November 26, 1999
Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study GroupJ M Kovarik, B D Kahan, P R Rajagopalan, et al.
Pageof 36